Overview


According to FutureWise analysis the market for Sickle Cell Disease Treatment in 2023 is US$ 1.2 billion, and is expected to reach US$ 1.68 billion by 2031 at a CAGR of 4.30%.

Sickle cell disease treatment has grown due to advances in anemia treatment. The growth of the global market for sickle cell disease treatment is largely attributed to medical advances. Several problems are associated with sickle cell disease, including a decrease in hemoglobin levels in the body. Hemoglobin is a protein contained in red blood cells, responsible for carrying oxygen throughout the body. In order to maintain a healthy blood supply, it is vital to maintain the quality and quantity of hemoglobin. Since the turn of the century, sickle cell disease treatment has seen an increase in demand. A large portion of the humongous revenues inflowing into the global sickle cell disease treatment market can be ascribed to this factor. Moreover, doctors and medical practitioners educate people about the health risks associated with hemoglobin deficiency. Globally, this factor has also played a significant role in the recent growth of the sickle cell disease treatment market. With the increasing need to treat diseases relating to blood plasma, the market for sickle cell disease treatment has been expanding globally. The disease of sickle cell can lead to several bodily disorders due to a lack of hemoglobin. For patients with low hemoglobin levels, quick treatment is recommended. In the coming years, this factor is expected to accelerate the growth of the global sickle cell disease treatment market. Investing in the sickle cell disease treatment market will grow in the coming years due to new avenues opening up.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Sickle Cell Disease Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Sickle Cell Disease Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  •  Novartis AG
  •  Global Blood Therapeutics Inc.
  •  Emmaus Medical, Inc.
  •  Addmedica
  •  Medunik USA Inc.
  •  Bristol-Mayers Squibb Company
  •  Sanofi SA
  •  Bluebird Biotechnology
  •  Pfizer Inc.
  •  Aruvant Sciences, Inc.
  •  Glycomimetics Inc.
  •  Editas Medicine, Inc.
  •  CRISPR Therapeutic

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Treatment Modality

  •  Blood Transfusion
  •  Bone Marrow Transplant
  •  Pharmacotherapy
    •  Hydroxyurea
    •  Branded Drugs
      •  Endari
      •  Adakveo
      •  Oxbryta
      •  Zynteglo
      •  CTX001
      •  Mitapivat
      •  FT-4202

By End User

  •  Hospitals
  •  Specialty Clinics
  •  Others

By Region

  •  North America
  •  Europe
  •  Asia-Pacific
  •  Latin America
  •  Middle East and Africa


  •  Tier 1 players- established companies in the market with a major market share
  •  Tier 2 players
  •  Emerging players which are growing rapidly
  •  New Entrants

  •  Growth prospects
  •  SWOT analysis
  •  Key trends
  •  Key data-points affecting market growth

  •  To provide with an exhaustive analysis on the Sickle Cell Disease Treatment Market By Treatment Modality, By End User and By Region.
  •  To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  •  To evaluate and forecast micro-markets and the overall market
  •  To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  •  To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  •  We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  •  The customization Mobility Care offered are free of charge with purchase of any license of the report
  •  You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Sickle Cell Disease Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Sickle Cell Disease Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Sickle Cell Disease Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Sickle Cell Disease Treatment Market, By Treatment Modality Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Bone Marrow Transplant
        2. Blood Transfusion
        3. Pharmacotherapy
         3.1. Hydroxyurea
         3.2. Branded Drugs
          3.2.1. Endari
          3.2.2. Adakveo
          3.2.3. Oxbryta
          3.2.4. Zyntelgo
          3.2.5. CTX001
          3.2.6. Mitapivat
          3.2.7. FT-4202

  • 8.   Sickle Cell Disease Treatment Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Other End Users

  • 9.   North America Sickle Cell Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Sickle Cell Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Sickle Cell Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Sickle Cell Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Sickle Cell Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Novartis AG
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Global Blood Therapeutics Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Emmaus Medical, Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Addmedica
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Medunik USA Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Bristol-Mayers Squibb Company
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Sanofi SA
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Bluebird Biotechnology
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Pfizer Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
         10. Aruvant Sciences, Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
          11. Glycomimetics Inc.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
          12. Editas Medicine, Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
          13. CRISPR Therapeutic
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients